AstraZeneca Offers About $10 Billion for Rhythm
The British drugmaker's bid for the obesity-focused company sent Rhythm's shares sharply higher.
Updated on Nov. 4, 2026 in Healthcare
AstraZeneca made an offer of about $10 billion to acquire Rhythm Pharmaceuticals, offering about $124 per share, according to the Wall Street Journal. Rhythm shares closed up 28% at $110.68 on the news.
Why it matters
The reported bid signals continued drugmaker interest in obesity and rare metabolic disorder treatments, a fast-growing area of pharmaceutical development. It also follows earlier expressions of interest that AstraZeneca renewed in recent months.
The reported offer of about $124 per share values Rhythm at roughly $10 billion, compared with a market capitalization of about $7.64 billion before the news. Rhythm's shares closed up 28% at $110.68, but whether the bid will be formally made or accepted has not been disclosed.
The players
AstraZeneca
A British multinational pharmaceutical company that develops prescription medicines across several therapeutic areas.
Rhythm Pharmaceuticals
A biopharmaceutical company focused on treatments for rare genetic metabolic disorders and severe obesity.
The details
AstraZeneca, a British drugmaker, reportedly offered about $124 per share for Rhythm Pharmaceuticals, a company that develops treatments for rare metabolic disorders and severe obesity. AstraZeneca declined to comment, and Rhythm did not immediately respond to requests for comment.
Timeline
October 2026: AstraZeneca offered about $124 per share for Rhythm.
November 4, 2026: The Wall Street Journal reported the bid, and Rhythm shares closed up 28%.
Market Landscape
Large drugmakers have pursued obesity and metabolic-disease assets since the commercial success of GLP-1 weight-loss medicines drew wide industry attention. A reported bid for Rhythm places AstraZeneca among companies seeking to expand their pipelines in this area.
A completed deal could change who controls Rhythm's obesity and rare metabolic treatments, which may affect the availability and pricing of those medicines for patients. For now, the offer is reported but not confirmed, so no change to patient access has taken effect.
The takeaway
Investors and patients should watch for official confirmation from AstraZeneca or Rhythm, since reported offers do not always result in completed transactions. Clear announcements will show whether the bid moves forward and on what terms.
Further reading
For more on how drugmakers are positioning themselves, see the Healthcare section.
